scholarly journals The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer

Medicine ◽  
2016 ◽  
Vol 95 (5) ◽  
pp. e2772 ◽  
Author(s):  
Soo Hyun Kwon ◽  
Seung Hyup Hyun ◽  
Joon-Kee Yoon ◽  
Young-Sil An ◽  
Young-Taek Oh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Metabolic Activity ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Small Cell ◽  
Small Cell Lung ◽  
Limited Stage

Continued Cigarette Smoking by Patients Receiving Concurrent Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer Is Associated With Decreased Survival

2003 ◽  
Vol 21 (8) ◽  
pp. 1544-1549 ◽  
Author(s):  
Gregory M.M. Videtic ◽  
Larry W. Stitt ◽  
A. Rashid Dar ◽  
Walter I. Kocha ◽  
Anna T. Tomiak ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Smoking Status ◽  
Small Cell ◽  
Small Cell Lung ◽  
Limited Stage ◽  
Treatment Interruptions ◽  
The Impact

Purpose: To determine the impact of continued smoking by patients receiving chemotherapy (CHT) and radiotherapy (RT) for limited-stage small-cell lung cancer (LSCLC) on toxicity and survival. Patients and Methods: A retrospective review was carried out on 215 patients with LSCLC treated between 1989 and 1999. Treatment consisted of six cycles of alternating cyclophosphamide, doxorubicin, vincristine and etoposide, cisplatin (EP). Thoracic RT was concurrent with EP (cycle 2 or 3) only. Patients were known smokers, with their smoking status recorded at the start of chemoradiotherapy (CHT/RT). RT interruption during concurrent CHT/RT was used as the marker for treatment toxicity. Results: Of 215 patients, smoking status was recorded for 186 patients (86.5%), with 79 (42%) continuing to smoke and 107 (58%) abstaining during CHT/RT. RT interruptions were recorded in 38 patients (20.5%), with a median duration of 5 days (range, 1 to 18 days). Median survival for former smokers was greater than for continuing smokers (18 v 13.6 months), with 5-year actuarial overall survival of 8.9% versus 4%, respectively (log-rank P = .0017). Proportion of noncancer deaths was comparable between the two cohorts. Continuing smokers did not have a greater incidence of toxicity-related treatment breaks (P = .49), but those who continued to smoke and also experienced a treatment break had the poorest overall survival (median, 13.4 months; log-rank P = .0014). Conclusion: LSCLC patients who continue to smoke during CHT/RT have poorer survival rates than those who do not. Smoking did not have an impact on the rate of treatment interruptions attributed to toxicity.

scholarly journals PD6-1-8: 18-FDG-PET based planning of limited stage small cell lung cancer changes radiotherapy fields: A planning study

2007 ◽  
Vol 2 (8) ◽  
pp. S427-S428
Author(s):  
Judith v. Loon ◽  
Rinus Wanders ◽  
Andre Dekker ◽  
Monique Hochstenbag ◽  
Gerben Bootsma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Small Cell ◽  
Small Cell Lung ◽  
Planning Study ◽  
Limited Stage

919 POSTER FDG-PET based planning of limited stage small-cell lung cancer changes radiotherapy fields: a planning study

2007 ◽  
Vol 5 (4) ◽  
pp. 124-125
Author(s):  
J. van Loon ◽  
D. De Ruysscher ◽  
M. Hochstenbag ◽  
G. Bootsma ◽  
W. Geraedts ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Small Cell ◽  
Small Cell Lung ◽  
Planning Study ◽  
Limited Stage

Optimal thoracic radiation dose in limited stage small cell lung cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 8562-8562
Author(s):  
Madhusmita Behera ◽  
Xinyan Zhang ◽  
Renjian Jiang ◽  
Rathi Narayana Pillai ◽  
Pretesh R Patel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Once Daily ◽  
Comorbidity Score ◽  
Limited Stage ◽  
Thoracic Radiation

8562 Background: Several studies have demonstrated improved overall survival in limited stage small cell lung cancer (LS-SCLC) patients (pts) with the addition of thoracic radiation therapy (RT) to chemotherapy. However, the optimal dose of thoracic RT when given daily, which is the most common practice pattern in the US, is yet to be firmly established. We analyzed outcomes associated with once-daily low dose (LD) RT relative to once-daily high dose (HD) RT for LS-SCLC in the National Cancer Data Base (NCDB). Methods: The NCDB was queried to capture pts with LS-SCLC treated with thoracic RT from 2004-2013. The cohort of pts that received 60 Gy (LD) was compared with the cohort that received RT ≥70 Gy (HD). The univariate (UV) association of overall survival (OS) was assessed using Cox proportional hazards models and log-rank tests. A multivariable (MV) Cox proportional hazard model and Kaplan-Meier (KM) analyses were performed to compare the LD vs. HD cohorts. Propensity score matching method was also implemented to reduce treatment selection bias. All analyses were performed using SAS Version 9.4. Results: A total of 5,159 pts (LD-3441; HD- 1718) were included in the analysis. Pt characteristics (LD/HD): median age 65/64 yrs; males 44/46%; whites 89/88%, academic centers 28/31%, Charlson-Deyo comorbidity score 0- 61%/64%; government insured 61/57%. 96% of pts in LD and 95% in HD cohorts had received chemotherapy. On MV analysis, no differences were found in OS between HD and LD RT(HR 0.98, p = 0.5), which was confirmed by KM analysis with 5-yr survival of 21% in LD vs 21.5% in HD (p = 0.8). On MV analysis of OS stratified by comorbidity score, LD was associated with significantly better survival compared to HD in pts with a comorbidity score of 1 and above (HR 0.87, p = 0.02). The LD group also had a better 5-yr survival than HD group in pts with higher comorbidity score (19% vs 14%, p = 0.01). No difference in survival was noted between the two cohorts for pts with no recorded comorbidities (HR 1.03, p = 0.6). Conclusions: In LS SCLC pts, survival was similar in pts who received daily RT of 60 Gy compared to those that received 70 Gy and above. In pts with worse performance status, those who received LD RT of 60 Gy had better survival.

scholarly journals Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis

2021 ◽  
Vol 13 ◽  
pp. 175883592098280
Author(s):  
Nadeem Bilani ◽  
Evan Alley ◽  
Leah Elson ◽  
Zeina Nahleh ◽  
Rafael Arteta-Bulos
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
National Database ◽  
National Cancer Database ◽  
Small Cell Lung ◽  
Limited Stage ◽  
The Impact

Background: While immune-based therapies have been approved for extensive-stage small cell lung cancer, there is limited data on the efficacy of immunotherapy in patients with limited-stage disease. Methods: We used the National Cancer Database to first evaluate factors associated with the inclusion of immunotherapy as part of the initial therapeutic course in patients diagnosed with limited-stage small cell lung cancer (LS-SCLC). Consequently, we evaluated the impact of this immunotherapy on 2-year and 5-year overall survival (OS). We did this by performing 1:1 matching for controls that did not receive immunotherapy, and comparing survival between cohorts using the Kaplan–Meier method. Results: A total of 98 patients with LS-SCLC received immunotherapy as part of their initial therapeutic regimen. Age and facility type were the only significant predictors of the use of immunotherapy. There was no statistically significant difference between matched case-control cohorts in median OS ( p = 0.985), 2-year OS ( p = 0.747), and 5-year OS ( p = 0.934). Conclusion: In this study using a large national database, we found that the inclusion of immunotherapy as part of the initial systemic therapy regimen was not significantly associated with improved OS in a cohort of LS-SCLC patients.

Hybrid scheme with carboplatin and etoposide intravenous (iv) and oral in patients with small cell lung cancer: Should we treat in a different way based on the age?

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e17515-e17515
Author(s):  
Andrea Ruiz-Valdepeñas ◽  
Magda Palka ◽  
Patricia Ibeas ◽  
Bernard Gaston Doger de Speville ◽  
Elena Almagro ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Median Overall Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Hybrid Scheme ◽  
Limited Stage ◽  
One Year

e17515 Background: The increase in longevity due to a better quality of life in old people makes possible the chemotherapy treatment in the most of patients with Small Cell Lung Cancer. The aim of this research is to evaluate if there are differences in overall survival according to the age (comparing older and younger than 65 years old), in patients treated with the same scheme of chemotherapy. Methods: Patients diagnosed with small cell lung cancer between years 2003 and 2010 and treated in our hospital by the scheme carboplatin 300mg/m2 IV on day 1, with etoposid 100mg/m2 per day (iv on day 1 and oral days two to five), were retrospective reviewed to evaluate the overall survival by group of age (older and younger than 65 years old). Results: 96 patients diagnosed of small cell lung cancer were treated in our hospital between 2003 and 2010 with the aforementioned scheme of chemotherapy. 70 of them were on extended stage, and 26 had limited stage; 54 were until 65 years old (56.25%) and 42 were older (43.75%). In extended disease, the elder than 65 presented an overall survival rate one year after the diagnosis of 38.3% (SE 9.3%) and at 18 months 10.2% (SE 6.3%), with a median overall survival of 10 months (Range 1 to 22 months). The younger than sixty five had an overall survival at 12 months of 23.8% (SE 6.6%), and at 18 moths of 5.4 (3.7%), non significant (p:0.437). Their median overall survival was 8.23 months, with a range of <1month to 24 months. In the group with limited stage, the sample older than 65 had a probability of overall survival 1 year after the diagnosis of 46,2% (Standard error (SE), 13.8%), and 23.1% (SE 11.7%) at 18 months, versus a 48.6% (SE 14,8%) at 12 months and 19.4% (SE 12.2%) in younger (p:0.708). The median overall survival in elder than 65 with Limited stage was 11.5 months (6 to 81 months), and for the younger 15 months (range 4 to 25 months). Conclusions: The hybrid scheme carboplatin 300mg/m2 IV on day 1, with etoposid 100mg/m2 per day (iv on day 1 and oral days 2 to 5), provides an acceptable overall survival, without significant differences comparing older and younger than 65 years old, both in limited and extended stage.

Sign in / Sign up

Export Citation Format

Share Document